Fonte: Blood. Nome do evento: ASH Annual Meeting and Exposition. Unidade: FMRP
Assuntos: TRANSPLANTE DE MEDULA ÓSSEA, HEMATOLOGIA, ANEMIA FALCIFORME
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KASSIM, Adetola A. et al. Outcomes of non-myeloablative HLA-haploidentical bone marrow transplant with thiotepa and post-transplant cyclophosphamide in children and adults with severe sickle cell disease, a phase ii trial: Vanderbilt global haploidentical transplant learning collaborative (VGC²). Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2020-141771. Acesso em: 08 set. 2024. , 2020APA
Kassim, A. A., de la Fuente, J., Alahmari, A. D., Eckrich, M. J., Hanna, R., Dhedin, N., et al. (2020). Outcomes of non-myeloablative HLA-haploidentical bone marrow transplant with thiotepa and post-transplant cyclophosphamide in children and adults with severe sickle cell disease, a phase ii trial: Vanderbilt global haploidentical transplant learning collaborative (VGC²). Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2020-141771NLM
Kassim AA, de la Fuente J, Alahmari AD, Eckrich MJ, Hanna R, Dhedin N, Horn BN, Black V, Gouveia RV, Seber A, Simões BP, Costa TC de M, Cunha RLG. Outcomes of non-myeloablative HLA-haploidentical bone marrow transplant with thiotepa and post-transplant cyclophosphamide in children and adults with severe sickle cell disease, a phase ii trial: Vanderbilt global haploidentical transplant learning collaborative (VGC²) [Internet]. Blood. 2020 ; 136 5 .[citado 2024 set. 08 ] Available from: https://doi.org/10.1182/blood-2020-141771Vancouver
Kassim AA, de la Fuente J, Alahmari AD, Eckrich MJ, Hanna R, Dhedin N, Horn BN, Black V, Gouveia RV, Seber A, Simões BP, Costa TC de M, Cunha RLG. Outcomes of non-myeloablative HLA-haploidentical bone marrow transplant with thiotepa and post-transplant cyclophosphamide in children and adults with severe sickle cell disease, a phase ii trial: Vanderbilt global haploidentical transplant learning collaborative (VGC²) [Internet]. Blood. 2020 ; 136 5 .[citado 2024 set. 08 ] Available from: https://doi.org/10.1182/blood-2020-141771